TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Volatility and Risk
TriSalus Life Sciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for TriSalus Life Sciences and Valneva, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
| Valneva | 2 | 0 | 3 | 0 | 2.20 |
Valuation & Earnings
This table compares TriSalus Life Sciences and Valneva”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $45.15 million | 5.55 | -$39.23 million | ($1.41) | -2.89 |
| Valneva | $197.56 million | 2.58 | -$130.33 million | ($1.87) | -2.88 |
TriSalus Life Sciences has higher earnings, but lower revenue than Valneva. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares TriSalus Life Sciences and Valneva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -60.85% | N/A | -69.91% |
| Valneva | -88.87% | -107.63% | -33.02% |
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Valneva
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
